Zacks Research Issues Negative Estimate for Cencora Earnings

Cencora, Inc. (NYSE:COR) – Equities researchers at Zacks Research lowered their Q1 2026 earnings per share estimates for Cencora in a research report issued on Wednesday, November 26th. Zacks Research analyst Team now anticipates that the company will earn $4.02 per share for the quarter, down from their previous forecast of $4.10. The consensus estimate for Cencora’s current full-year earnings is $15.37 per share. Zacks Research also issued estimates for Cencora’s Q2 2026 earnings at $4.86 EPS, Q3 2026 earnings at $4.31 EPS, Q4 2026 earnings at $4.28 EPS, FY2026 earnings at $17.47 EPS, Q2 2027 earnings at $5.27 EPS, Q3 2027 earnings at $4.82 EPS, Q4 2027 earnings at $4.96 EPS, FY2027 earnings at $19.34 EPS and FY2028 earnings at $21.01 EPS.

A number of other brokerages have also weighed in on COR. Weiss Ratings lowered Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday. Mizuho upped their target price on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. JPMorgan Chase & Co. boosted their price target on shares of Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Evercore ISI set a $400.00 price objective on shares of Cencora and gave the company an “outperform” rating in a research report on Thursday, November 6th. Finally, Robert W. Baird lifted their target price on Cencora from $355.00 to $395.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Eight investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $371.09.

Cencora Stock Performance

NYSE COR opened at $350.17 on Monday. The company has a 50 day moving average of $338.10 and a 200-day moving average of $308.78. Cencora has a 1-year low of $223.92 and a 1-year high of $377.54. The firm has a market cap of $67.89 billion, a price-to-earnings ratio of 44.05, a PEG ratio of 1.71 and a beta of 0.63. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The company had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. During the same quarter in the previous year, the company earned $3.34 EPS. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.7%. This is an increase from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend was Friday, November 14th. Cencora’s payout ratio is currently 30.19%.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 31,350 shares of the business’s stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the transaction, the chairman directly owned 305,913 shares in the company, valued at $88,671,942.18. The trade was a 9.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $366.64, for a total transaction of $1,868,397.44. Following the completion of the transaction, the chief executive officer owned 65,746 shares in the company, valued at approximately $24,105,113.44. This represents a 7.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 46,640 shares of company stock valued at $14,099,338. Corporate insiders own 10.80% of the company’s stock.

Institutional Investors Weigh In On Cencora

Large investors have recently bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC increased its stake in Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after acquiring an additional 35 shares during the last quarter. Costello Asset Management INC acquired a new stake in Cencora in the first quarter valued at about $28,000. IAG Wealth Partners LLC acquired a new position in Cencora during the third quarter worth about $30,000. Vermillion & White Wealth Management Group LLC boosted its stake in shares of Cencora by 69.4% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after purchasing an additional 43 shares in the last quarter. Finally, Cloud Capital Management LLC bought a new stake in shares of Cencora during the 3rd quarter valued at approximately $31,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.